Skip to content

Study · Not a test of the peptide alone · 2006

2 results

Gene transfer of pro-opiomelanocortin prohormone suppressed the growth and metastasis of melanoma: involvement of alpha-melanocyte-stimulating hormone-mediated inhibition of the nuclear factor kappaB/cyclooxygenase-2 pathway.

Liu GS, Liu LF, Lin CJ, Tseng JC, Chuang MJ, Lam HC, Lee JK, Yang LC, Chan JH, Howng SL, Tai MH

Molecular pharmacology3 Nov 2005Cited by 33 (Europe PMC)

PMID16269535 (opens in a new tab)DOI10.1124/mol.105.015404 (opens in a new tab)PepBankPUB-16269535
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 used as an alpha-MSH antagonist abolished POMC-induced inhibition of NFkappaB activity.

    In plain wordsIn mice, GHRP‑6 used as an antagonist blocked the inhibition of NFkappaB activity from POMC gene delivery.

    Peptide
    GHRP-6
    Outcome
    IncreaseNFkappaB activity
    Study

    micen: not reported in source

    POMC gene delivery melanoma model
    Comparator
    POMC gene delivery without GHRP-6
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    whereas application of the alpha-MSH antagonist growth hormone-releasing peptide-6 (GHRP-6) abolished the POMC-induced inhibition of NFkappaB activities and melanoma growth in mice.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 used as an alpha-MSH antagonist abolished POMC-induced inhibition of melanoma growth.

    In plain wordsIn mice, GHRP‑6 used as an antagonist blocked the inhibition of melanoma growth from POMC gene delivery.

    Peptide
    GHRP-6
    Outcome
    IncreaseMelanoma growth
    Study

    micen: not reported in source

    POMC gene delivery melanoma model
    Comparator
    POMC gene delivery without GHRP-6
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    whereas application of the alpha-MSH antagonist growth hormone-releasing peptide-6 (GHRP-6) abolished the POMC-induced inhibition of NFkappaB activities and melanoma growth in mice.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.